Sequential Therapy in Metastatic Renal Cell Carcinoma.
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The authors are practicing medical oncologists at the US Oncology Network, the largest community-based network of oncology providers in the country, and represent the leadership of the Network's Genitourinary Research Committee. We outline our thought process in approaching sequential therapy of mRCC and the use of real-world data to inform our approach. We also highlight the evolving literature that will impact practicing oncologists in the near future.
US Oncology Research, Houston, TX, USA.
Bradford R
BR
Hirsch
US Oncology Research, Houston, TX, USA.
John M
JM
Burke
US Oncology Research, Houston, TX, USA.
Manish
M
Agrawal
US Oncology Research, Houston, TX, USA.
Ralph J
RJ
Hauke
US Oncology Research, Houston, TX, USA.
Thomas E
TE
Hutson
US Oncology Research, Houston, TX, USA.
Gury
G
Doshi
US Oncology Research, Houston, TX, USA.
Mark T
MT
Fleming
US Oncology Research, Houston, TX, USA.
Nicholas J
NJ
Vogelzang
kidney cancer; renal cell carcinoma; sequential therapy